(Updates Oct 16 story with company comment in bullet points 4-5) Oct 19 (Reuters) – Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)